GP
ALPN

GLG Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

GLG Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,689
Closed -$300K – 512
2015
Q4 		$300K Sell
9,689
-4,778
-33% -$163K 0.01% 407
2015
Q3 		$751K Buy
14,467
+6,654
+85% +$437K 0.02% 377
2015
Q2 		$473K Buy
+7,813
New +$465K 0.01% 404

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

GLG Partners's ALPN Position: Q1 2016 in Review

GLG Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2016, closing a stake of 9,689 shares — an estimated $300K sold.

GLG Partners first reported a position in ALPN in Q2 2015 and held it in 3 quarters. The position peaked at $751K in Q3 2015. 58 funds tracked by Wall St. Rank hold ALPN as of Q1 2016.

  • GLG Partners reported no remaining Alpine Immune Sciences Inc position as of Q1 2016 after selling out during the quarter.
  • GLG Partners sold 9,689 Alpine Immune Sciences Inc shares in Q1 2016, an estimated $300K.
  • GLG Partners first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 3 quarters.
  • GLG Partners's Alpine Immune Sciences Inc position peaked at $751K in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2016.

Based on GLG Partners's 13F filing for Q1 2016, filed 16 May 2016.